BEDFORD, Mass., Dec. 29, 2009 /PRNewswire/ -- Hologic, Inc. (Hologic or the Company) (Nasdaq: HOLX), a leading developer, manufacturer and supplier of premium diagnostics, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, is using the annual meeting of the American Society for Radiology Oncology (ASTRO) at McCormick Place in Chicago, November 1 through 5, 2009, to feature the MammoSite® ML radiation therapy system.
Hologic's MammoSite therapy system, first cleared by the FDA in 2002, is the most widely utilized and accepted method of accelerated partial breast irradiation (APBI) in the United States. With its multi-lumen design, the new MammoSite ML device gives radiation oncologists the ability to shape the radiation dose for typical cases and treat patients who are otherwise not appropriate candidates for traditional brachytherapy.
By employing the MammoSite system, the radiation oncologist can deliver targeted radiation therapy directly to the area where cancer is most likely to recur, allowing a full course of radiation to be delivered in just five days. Additionally, targeted therapy of the breast limits radiation exposure to normal, healthy tissue. This targeting helps minimize side effects such as skin discoloration and scarring, burning, fatigue, and damage to surrounding organs.
David Harding, senior vice president of Hologic's interventional breast solutions business, stated, "MammoSite ML is designed to provide radiation oncologists a lot more flexibility. And, we believe the parallel lumen design offers increased patient comfort and enables efficient treatment planning. With MammoSite ML, radiation oncologists should be able to easily satisfy the current clinical recommendation that the dose to the skin and ribs be maintained to less than 125 percent of the prescription dose."
"ASTRO is the perfect venue to feature MammoSite ML," Mr. Harding added. "The radiation oncology community will see firsthand our commitment to expanding the adoption of accelerated partial breast irradiation." Radiation oncologists, radiation oncology nurses, medical physicists, radiation therapists, dosimetrists, and biologists comprise ASTRO's more than 10,000 members, making it the largest radiation oncology organization of its kind.
"The five-year American Society of Breast Surgeons MammoSite Breast Brachytherapy Registry results are also being presented at this meeting," Harding noted. "The data from the study is expected to show once again that treatment with the MammoSite system resulted in acceptable ipsilateral breast tumor recurrence and axillary recurrence rates that are comparable with standard whole breast radiation therapy. We also expect the registry data to show excellent breast cancer-specific survival. "
In October Hologic began a limited market launch of MammoSite ML to train physicians and scale up for national distribution. The Company expects a full commercial launch by year end.
Please see www.mammosite.com for additional information on the MammoSite targeted radiation therapy system.
About Hologic, Inc.
Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women. Hologic's core business units are focused on breast health, diagnostics, GYN surgical, and skeletal health. Hologic provides a comprehensive suite of technologies with products for mammography and breast biopsy, radiation treatment for early-stage breast cancer, cervical cancer screening, treatment for menorrhagia, permanent contraception, osteoporosis assessment, preterm birth risk assessment, mini C-arm for extremity imaging and molecular diagnostic products including HPV and reagents for a variety of DNA and RNA analysis applications.
Forward-Looking Statement Disclaimer
This News Release may contain forward-looking information that involves risks and uncertainties, including statements about the use of the MammoSite and MammoSite ML targeted radiation therapy systems. There can be no assurance the system will achieve the benefits described herein and that such benefits will be replicated in any particular manner with respect to an individual patient as the actual effect of the use of the MammoSite targeted radiation therapy systems can only be determined on a case-by-case basis depending on the particular circumstances and patient in question. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to the data or statements presented herein to reflect any change in the Company's expectations or any change in events, conditions or circumstances on which any such data or statements are based. Certain factors that could adversely affect the Company's business and prospects are described in Hologic filings with the Securities and Exchange Commission.
Hologic and MammoSite are trademarks and/or registered trademarks of Hologic, Inc., and/or its subsidiaries in the United States and/or other countries.
Interventional Breast Solutions